Reviva Pharmaceuticals to Present on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual Scientific Convention of the Society of Biological Psychiatry

Apr 20, 2023 | Press Releases

CUPERTINO, Calif., April 20, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2022 Financial Results and Recent Business Highlights

Mar 30, 2023 | Press Releases

– Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023 – – Completed majority of non-clinical and clinical prelaunch measures for brilaroxazine New Drug Application (NDA)...

Reviva Pharmaceuticals to Present at the 35th Annual Roth Conference

Mar 7, 2023 | Press Releases

CUPERTINO, Calif., March 07, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference

Jan 31, 2023 | Press Releases

Cupertino, Calif., Jan. 31, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals Announces Letter to Shareholders

Jan 4, 2023 | Press Releases

CUPERTINO, Calif., Jan. 04, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...